Мероприятия Общества

Russian Society of Clinical Oncology (RUSSCO) webinar «Practical aspects of treatment of patients with metastatic colorectal cancer» (20 May 2021, 15:00-16:35)

Russian Society of Clinical Oncology (RUSSCO) webinar
«Practical aspects of treatment of patients with metastatic colorectal cancer»

20 May 2021, 15:00-16:35


Alexey A. Tryakin Alexey A. Tryakin
MD, Professor, Deputy Director for Research, Head of the Chemotherapeutic Department No.2
of the N.N. Blokhin National Research Medical Center of Oncology of the Ministry of Health
of the Russian Federation, Member of the Board of RUSSCO, Chairman of the working group
on the development of Practical recommendations of RUSSCO,

Mario Scartozzi Mario Scartozzi
MD Full Professor and Chair Head,
Medical Oncology Director,
School of Nursing University of Cagliari,
University Hospital Cagliari,

Venue: Moscow, online.

Participants: oncologists, surgeons, chemotherapists, specialists in related fields.

Simultaneous translation will be provided.


15:00-15:05 – Welcome speech
Alexey A. Tryakin MD (Moscow)

15:05-15:35 – How to achieve resectability of CRC liver metastases: practical approaches on the example of a clinical case
Alexey A. Tryakin MD (Moscow)
15:35-15:45 – Discussion

15:45-16:15 – How the choice of the 1st line therapy contributes to the maximum increase in the life expectancy of a patient with mCRC – theory and practice
Mario Scartozzi MD (Italy)
16:15-16:35 – Discussion. Q&A session

Content of the lectures:

  1. Alexey Tryakin, MD, will present clinical data and expert opinion on topic of conversion therapy of RAS wt patients with LLD mCRC. Presentation will be arranged around clinical case of a patient with primarily unresectable mCRC who received 1st line cetuximab + doublet CT regimen, achieved resectability of liver metastases that were successfully resected. After PD the patient received 2nd line bevacizumab-containing regimen, then after PD2 – regorafenib, and after PD3 cetuximab was successfully reintroduced. (The expert is convinced of the need to use regorafenib or only CT regimens between bevacizumab-containing line and reintroduction of cetuximab to overcome possible resistance to cetuximab caused by bevacizumab according to REVERCE, COMETS trials).
  2. Dear Mario Scartozzi, MD, it is assumed that your presentation will also be built around a clinical case. We would like you to present the clinical data about choosing of 1st line therapy for patients with RAS wt unresectable mCRC and how this choice will affect an efficacy and the options of later therapy lines. We will be grateful if you can justify the reintroduction of cetuximab±CT in the 3rd line after successful use of cetuximab+CT in the 1st line and bevacizumab+CT in the 2nd line on your personal experience of treatment of such a patient.